Characteristics and origin
In terms of its chemical nature and structure, alemtuzumab belongs to the category of humanized monoclonal antibodies. This drug is specifically designed to target certain structures of the human immune system, which determines its specific pharmacological activity.
Mechanism of action and pharmacokinetics
The main target for the drug is the CD52 receptor, which is located on lymphocytes.
- By binding to its target, the drug triggers lysis (destruction) of lymphocytes.
- Active clearance of the destroyed cells from the bloodstream takes place.
- The pharmacological effect is long-lasting and persists for up to one year after administration.
Indications and dosage regimens
Depending on the treatment goals, the drug is used in various regimens:
- Monotherapy — indicated for chronic lymphocytic leukemia.
- Combination therapy — used in organ transplantation procedures. In these cases, it is combined with agents such as glucocorticoids, tacrolimus, or sirolimus to prevent rejection.
Side effects and risks
Therapy with this medicinal product is associated with certain risks and adverse reactions:
- Cytokine release syndrome — develops predominantly upon the very first administration of the drug.
- Hematological disorders — anemia and neutropenia are frequently observed, and pancytopenia may develop in rarer cases.
Briefly: answers to topical questions
What side effects are characteristic of alemtuzumab therapy?
Alemtuzumab therapy is characterized by a wide spectrum of adverse reactions, including infusion-related, hematological, infectious, and autoimmune complications.
The main side effects include:
- Infusion reactions — acute allergic reactions and "cytokine release syndrome" upon the first administration of the drug.
- Hematological disorders — development of anemia, neutropenia, and, in rarer cases, pancytopenia.
- Infections — increased risk of opportunistic infections (including listeriosis and progressive multifocal leukoencephalopathy), as well as potential reactivation of latent infections.
- Autoimmune complications — thyroid pathology, immune thrombocytopenia (ITP), and other secondary autoimmune reactions.
By what route is alemtuzumab administered into the body?
Alemtuzumab is administered into the body via the intravenous route.
The recommended dosing regimen is 12 mg intravenously as an infusion. The standard treatment scheme comprises two consecutive courses of therapy: the patient receives five infusions during the first year, and three infusions are prescribed for the second year.
For the treatment of which autoimmune demyelinating disease is alemtuzumab used?
Alemtuzumab is used for the treatment of multiple sclerosis.
The drug belongs to disease-modifying antirheumatic/antifertility/anticonvulsant... wait, disease-modifying therapies for multiple sclerosis (DMTs). Therapy requires careful monitoring: a prolonged period to achieve the full effect is observed over the first 18 months, and the first efficacy evaluation milestone occurs at 30 months. Regular blood count monitoring and screening for the prevention of latent infection reactivation are also required.
AlemtuMAB targets CD52 and causes a STORM upon the first administration.
Class and exam questions
What structural type does alemtuzumab belong to?
It is a humanized monoclonal antibody drug.
What is the cellular target of this drug?
The target is the CD52 receptor located on lymphocytes.
What disease is treated with alemtuzumab monotherapy?
As monotherapy, the drug is used for chronic lymphocytic leukemia.
What drugs is alemtuzumab combined with in organ transplantation?
It is combined with glucocorticoids, tacrolimus, or sirolimus.
What else to study on this topic
- Structure and production of humanized monoclonal antibodies
- Physiological role of the CD52 receptor in the body
- Pathogenesis of cytokine release syndrome upon administration of biological products
- Criteria for selecting combination therapy in organ transplantation
- Management of hematological disorders (anemia and neutropenia)
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Alemtuzumab" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Agents Regulating Immune Processes"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.